The firm said revenues for its discovery and analytical solutions business rose 1 percent year over year while revenues from diagnostics rose 8 percent.
The investment bank, which maintained its $60 price target for the company's stock, said it is looking for signs of revenue acceleration.
PerkinElmer may be nearing an FDA submission for a panel based on technology from the University of Washington, amid a push for state-mandated screening programs.
The company said the divestiture of its medical imaging business in the fourth quarter reduced revenues to below previous guidance.
The bank rated companies like Thermo Fisher Scientific and Agilent at Buy, Illumina and PerkinElmer at Hold, and Myriad Genetics and Luminex at Sell.
The agreement with PerkinElmer's Wallac Oy subsidiary will bring Mobidiag's real-time PCR-based gastrointestinal tests to a new market.
Executives provided updates on their companies at the 35th Annual JP Morgan Healthcare Conference in San Francisco.
Tulip Diagnostics Private provides in vitro diagnostic reagents, kits, and instruments to labs, and government and private healthcare facilities in India.
The companies will merge 10x's Chromium system and PerkinElmer's automation solutions into a combined NGS solution for researchers.
The company said the divestiture to Varian Medical Systems would allow it to concentrate on investing in high-growth parts of its business.
A new study catalogues the genome and evolutionary history of the oak family, UPI reports.
Dog DNA testing is a growing market, but there's still a lot of uncertainty about the accuracy of the results, the Boston Globe says.
A University of South Florida researcher is testing bone fragments to determine if they belong to Amelia Earhart.
In Cell this week: antisense Piwi-interacting RNA responses to endogenous retroviruses, proteomic patterns in hepatocellular carcinoma, and more.